Browse Technologies
Browse Technologies
Technology Keyword Search
Immunology/Autoimmune Diseases
Search Results
Displaying: 11 - 17 of 17 Results
Protein-based therapies using quantitatively designed proteins
A bipartite, quantitatively designed protein having two discrete ligands and a linker; one ligand having the ability to strongly bind to a particular cell, the other having the ability to affect a target only when the previous ligand binds. For many…
DBD
- Grant Zimmermann
Investigators
- Pamela Silver
- Pablo Cironi
- David Miguez
Novel methods for generating regulatory T-cells
Regulatory T-cells (Tregs) are key mediators of peripheral tolerance that can actively suppress effector T-cells, inhibit inflammation and mediate self-tolerance. Unlike naturally occurring Tregs (nTregs) which develop in the thymus,…
DBD
- Irit Ben-Chelouche
Investigators
- Arlene Sharpe
- Loise Francisco
- Vijay Kuchroo
Novel target in NK cell mediated antigen specific memory responses
The von Andrian laboratory discovered a novel mechanism for inducing antigen specific immunological memory. Their research examines the role of a molecular target not previously known to be associated with the natural killer (NK) cell mediated…
DBD
- Irit Ben-Chelouche
Investigators
- Ulrich von Andrian
- Silke Paust
Bisphosphonates as novel adjuvants to enhance the adaptive immune response, validated with common types of vaccine antigens and commercial vaccines
Despite decades of adjuvant research, only a handful of adjuvants have been approved in seven major global markets and only two (Alum and GSK’s AS04) are licensed in the US. The availability of additional adjuvants has been minimized due to…
DBD
- Irit Ben-Chelouche
Investigators
- Ulrich von Andrian
- Matteo Iannacone
- Elena Tonti
- Elliott Moseman
Control of host homeostatic immunity by a microbiome-derived immunomodulatory lipid
Akkermansia muciniphila, a species of the human gut microbiome, has been robustly associated with positive systemic effects on host metabolism and obesity, favorable response to checkpoint blockade in cancer immunotherapy, and maintenance of…
DBD
- Grant Zimmermann
Investigators
- Jon Clardy
RGMb-deficient T cells for overcoming resistance to immune checkpoint blockade
Immune checkpoint blockade therapies targeting PD-1 or PD-L1 have been approved for more than 25 different tumors. However, many patients do not respond to PD-1/PD-L1 checkpoint blockade. The Sharpe lab at Harvard Medical School has identified that…
DBD
- Grant Zimmermann
Investigators
- Arlene Sharpe
- Dennis Kasper
PD-L2 modulated dendritic cells for cancer immunotherapy
Immune checkpoint blockade therapies targeting PD-1 or PD-L1 have been approved for more than 25 different tumors. However, many patients do not respond to PD-1/PD-L1 checkpoint blockade. The Sharpe lab has identified that dendritic cells (DCs) with…
DBD
- Grant Zimmermann
Investigators
- Arlene Sharpe
- Dennis Kasper